Zika virus: laboratory diagnosis

Similar documents
Arbovirus Reports 2015

Centers for Disease Control and Prevention Zika Diagnosis: Challenges and Opportunities

Public Health Image Library. CDC/ Cynthia Goldsmith. Image #

Arbovirus Epidemiology and Diagnosis Educational Session Curacao 2016 R. Steingrover Clinical Microbiologist ADC

Zika Virus in the Primary Care Setting

Zika virus infection Interim clinical guidance for Primary Care

ZIKA VIRUS SHIPPING SOLUTIONS

Zika: Deet, There It Is. Anna Powell, MD Reproductive Infectious Disease Fellow THEGOS

ZIKA VIRUS. Epic and aspects of management

Skin and joint manifestations of

: AccuPower ZIKV(DENV, CHIKV) Multiplex Real-Time RT-PCR Kit. Copyright, Bioneer Corporation. All rights reserved.

Zika Virus Guidance for Medical Providers. Denise Smith, PHN, MPA Director of Disease Control Kern County Public Health Services Department

ZIKA VIRUS. John J. Russell MD May 27, 2016

What s Lurking out there??????

Laboratory Testing for West Nile Virus Infections Testing Human & Non-Human Tissues

Zika Virus Basics. Flaviviridae Flavivirus Disease Vector Vaccine *Dengue (serotypes 1-4) Zika Virus Basics. Zika Virus Transmission Cycle

DIAGNOSTICS ALGORITHMS IN DENGUE INFECTIONS

Dengue: The next vaccine preventable disease? Prof John McBride James Cook University

Prevention of transfusion-transmitted arboviruses in French Polynesia

Zika and other Flaviviruses

Geneva, March Consultation background

ZIKA VIRUS TESTING GUIDANCE, UPDATED 7/20/2016

When infections go viral Zika Virus

Exchange Program. Thailand. Mahidol University. Mahidol-Osaka Center for Infectious Diseases (MOCID) Date: 2013/06/05~2013/07/04

Objectives. Dengue, Chikungunya and Zika Virus Infection: Answers to Common Questions. Case 1. Dengue Introduction 10/15/2018

Everything you ever wanted to know about Zika Virus Disease

Appendix I (a) Human Surveillance Case Definition (Revised July 4, 2005)

What is Zika virus? What are the symptoms and complications of Zika virus infection? Are cases expected in Canada?

Role of a ZIKV CHIM in vaccine evaluation. Anna Durbin Johns Hopkins Bloomberg School of Public Health WHO Zika Workshop, Geneva 2 June 2017

Relevant Communicable Diseases in HCT/Ps

KILLER BITES: Mosquito-Borne Viruses Jon Mark Hirshon, MD, MPH, PhD

Building Zika preparedness in the Region of the Americas: research response

ZIKA VIRUS OUTBREAK. JANET B. EDDY M.D. KU-WICHITA PGY2 OBSTETRICS AND GYNECOLOGY RESIDENCY Dominican Republic 2016

Case Classification West Nile Virus Neurological Syndrome (WNNS)

Zika virus: a new global threat for Dr Gina McAllister Clinical Scientist, Virology

An Introduction to Dengue, Zika and Chikungunya Viruses

The Zika Crisis: Where, What and USG/WHO? Brian R. Moyer BRMoyer & Associates, LLC Bedford, NH

Zika Virus: The Olympics and Beyond

Appendix B: Provincial Case Definitions for Reportable Diseases

Update on Transfusion- Transmitted Infectious Diseases

This memo is intended to provide information to NC clinicians and laboratories regarding diagnosis, management and reporting of Zika virus infection.

European Centre for Disease Prevention and Control. Zika virus disease

Dengue. (Also Known as Dengue Fever, Dengue Hemorrhagic Fever, and Breakbone Fever)

Guidance for Investigation and Management of Zika Virus Infection

ARIZONA ARBOVIRAL HANDBOOK FOR CHIKUNGUNYA, DENGUE, AND ZIKA VIRUSES

Human B Cell Responses to Influenza Virus Vaccination

SEROLOGICAL DIAGNOSIS OF DENGUE INFECTIONS

Zika Virus Outbreak & Zika Congenital Syndrome. Regional Situation and Response

Zika Virus. Division of Infectious Disease Department of Internal Medicine Global Health Program Conference Dora Lebron, MD Alexandra Stang, MD

Test Definition: FMCPS Meningoencephalitis Comprehensive Panel (Serum)

West Nile Virus. By Frank Riusech

Zika Virus. Frequently Asked Questions: Zika Virus and Pregnancy Version

Fact sheet. Yellow fever

ARIZONA ARBOVIRAL HANDBOOK FOR CHIKUNGUNYA, DENGUE, & ZIKA VIRUSES

Vector-Borne Diseases Update: Maricopa County

Zika Virus Update March 21, 2018

TO: Physicians, other Healthcare Providers, and Laboratories. Please distribute a copy of this information to each provider in your organization.

THE ZIKA VIRUS. August 3, Sonia G. Pandit, MPH MBA Chief Executive Officer The Pandit Group

DENGUE AND BLOOD SAFETY. Ester C Sabino, MD, PhD Dep. of Infectious Disease/Institute of Tropical Medicine University of São Paulo

Zika Virus and Prevention in Mississippi

Presentation Overview

Testing - Pregnant Women

Test Name Results Units Bio. Ref. Interval

Test Name Results Units Bio. Ref. Interval

Zika Virus. Maternal & Fetal Effects. John P. Elliott, MD Medical Director, Valley Perinatal Services Phoenix, Arizona

Chikungunya Virus: The Canadian Perspective

Division of Virology, National Institute for Medical Research, Mill Hill, London, NW7 IAA. (Accepted I3 December I973)

Zika Virus. ZIKA VIRUS & PREGNANCY Stephen Champlin, M.D. FLAVIVIRIDAE VIRUS SPECTRUM. Virus family Flaviviridae

Travel: Chikungunya, Zika,.. New worries

Updates in Infectious Diseases. Kelley Struble, DO, MS St. John Physicians Infectious Disease September 30, 2016

ZIKA Jordan H. Perlow MD Banner University Medical Center Division of Maternal Fetal Medicine Phoenix Perinatal Asoociates

Fact Sheet for Health Care Providers: Interpreting Results from the Aptima Zika Virus assay. September 7, 2016

Carol M. Smith, M.D., M.P.H. Commissioner of Health and Mental Health Ulster County Department of Health and Mental Health May 20, 2016

North Carolina Department of Health and Human Services Division of Public Health

Supplementary Information for. Diagnosis of Zika virus infection on a nanotechnology platform

ARBOVIRAL RISKS TO BLOOD SAFETY IN AUSTRALIA. Clive Seed Australian Red Cross Blood Service ISBT TTD-WP meeting 26 June, 2015

The Emergence of Zika Virus and Other Arboviruses: Public Health Impacts At Home and Abroad

Zika Virus Update for Emergency Care Providers

Epidemiology and entomology of the Zika virus outbreak

Zika. Nicole Evert, MS Zoonosis Control Branch Department of State Health Services Austin, Texas

A RELOOK AT ZIKA VIRAL INFECTION AND ITS LATEST OUTBREAK IN INDIA

Emerging TTIs How Singapore secure its blood supply

HIV Test Technologies, Best Practices, and New Algorithm. Jenny R. McFarlane DSHS HIV Prevention and Care Branch

Emergence du Chikungunya dans les Antilles et caractéristiques virologiques de l épidémie

EDUCATIONAL COMMENTARY ZIKA VIRUS

ZKV and Guillain-Barré Syndrome. Silvia N. Tenembaum Pediatric Neurologist

Appendix B: Provincial Case Definitions for Reportable Diseases

Outbreaks of Zika Virus: What Do We Know? Presented by Dr Jonathan Darbro Mosquito Control Lab, QIMR Berhgofer 15 September 2016

Clinical Policy: Diagnostic Testing for Zika Virus Reference Number: CP.MP.111 Effective Date: 06/16

Zika Virus Outbreak in the Americas. J. David Beckham MD Associate Professor of Medicine Division of Infectious diseases University of Colorado SOM

Zika Virus Dr Conor Doherty

Module Three About Zika Virus: What is Known and Not Known

FY 2017 President s Budget Request Overview for the National Center on Birth Defects and Developmental Disabilities

Dengue Fever & Dengue Hemorrhagic Fever Annual Reports to WHO

Robust Inactivation of Yellow Fever Virus 17D Vaccine Strain can be achieved by Photochemical Treatment of Platelet Concentrates

What is the role of animal models in studying protective titres and the need for establishing surrogates/correlates of protection?

Appendix B: Provincial Case Definitions for Reportable Diseases

Diagnostics RDT / POC Technology for ZIKA related infections

The shifting landscape of Zika virus laboratory testing during the rapidly changing epidemic

Fight the Bite Zika Virus Webinar District of Columbia Department of Health

Transcription:

Zika virus: laboratory diagnosis Dr Linda Hueston Principal Scientist Arbovirus Emerging Diseases Unit CIDMLS-ICPMR Westmead Hospital Linda.Hueston@health.nsw.gov.au

Laboratory Diagnosis Flaviviruses >70 members of the family All cross react with each other but don t cross protect Antigen hall of mirrors Exhibit antibody dependent enhancement Test interpretation is critical Often requires testing against panels of flaviviruses Need clinical, travel and vaccination history

Laboratory Diagnosis Virus isolation Sine que non Difficult to obtain with most arboviruses as viraemia is low and short lived in humans Antigen detection ELISA based using monoclonal antibodies PCR Serology Majority of diagnoses are achieved serologically

Laboratory Diagnosis Serology Neutralisation (quantitative) Most sensitive & specific Requires use of live virus Haemagglutination inhibition (quantitative) Cross reactive Need to be able to make own antigen CF (quantitative) Short lived, more specific than HI but still some cross reactivity Need to make own antigen

Laboratory Diagnosis Serology IFA (semi quantitative or quantitative) In-house need to make slides Commercial slides available but not validated ELISA In- house ELISA (semi quantitative or quantitative) IgG IgM Defined epitope blocking ELISA Commercial ELISA (semi quantitative) IgG IgM

Virus isolation for Zika Established cultures of ZIKV grow well in a variety of mammalian and insect cell lines The virus has been very difficult to isolate from primary specimens Partly due to the almost universally low to very low viral loads in clinical specimens. Culture methods are reserved for specialised reference laboratories, Always worth attempting as isolates are extremely valuable

Key points laboratory testing Nucleic acid test Real-time rtpcr assay for detection of viral RNA Serum - detectable 3 to 7 days (Israeli study suggests RNA detectable in whole blood for up to 58 days) Urine - detectable up to a month Semen - detectable up to 2 weeks (occ cases >92 days) Shorter in secondary flavi infections NEGATIVE PCR DOES NOT EXCLUDE INFECTION

Key points laboratory testing Nucleic acid test Longest known period between infection & sexual transmission to another 31-42 days post onset Variability across sample type Don t know if presence of RNA indicates ability to transmit the virus NEGATIVE PCR DOES NOT EXCLUDE INFECTION 80% of serologic diagnoses were PCR negative

Serologic testing for Zika Neutralisation (use 90% endpoint, titres 20) Detects total antibody, Appears within 3 to 5 days Detectable for decades Most specific particularly in primary infections Some cross reactivity in non primary infections

Serologic testing for Zika IFA ELISA Detects IgG and IgM IgM detectable within 5 to 7 days for 8 to 10 weeks IgG detectable at 7 to 10 days for decades Some commercial slides available but not validated CROSS REACTIVE Commercial Euroimmun IgM detectable 8 to 12 days for 6 to 8 weeks IgG detectable 18 to 21 days NOT SPECIFIC

Laboratory Diagnosis Serology testing for Zika virus ELISA Commercial Euroimmun Cross reactions in IgM with YF, Den, JE, Kunjin/West Nile, Kokobera Cross reactions in IgG with YF, Den, JE, Kunjin/WNV, MVE, Kokobera, Stratford and Edge Hill Also missed early infections suggest repeat sample 21 days post onset Best used as a screen for negatives (if two samples are tested) Positives should be sent for confirmation

Key points laboratory testing Serology Cross reactivity presents laboratory diagnostic challenges Study released 2016 suggests that presence of preexisting dengue antibody may lead to an antibody dependent enhancement of Zika infection May explain the severity of disease seen in the Americas where dengue and YFV are endemic This has implications for vaccination options

Key points laboratory testing Serology In Australia antibody testing is being used as A routine antenatal screen A routine STD screen Regardless of travel and clinical history Given the issues with flavivirus serology this could lead to problems if patients return +ve results

Key information for laboratory testing Clinical history Onset date of symptoms Travel history dates of travel, countries visited, length of stay, type of trip. Vaccination history YFV, JE, TBE Past medical history any previous history of flavivirus infection

Limitations Infection may not be excluded on one sample alone Negative PCR does not exclude infection and should only be performed in symptomatic patients 80% of PCR negative symptomatic patients were IgM positive Follow-up any pos PCR with serology Follow up positive IgM s Titrate positive IgG and IgM (titres valuable) Test against a panel of flaviviruses to investigate cross reactivity These results suggest past infection with Zika virus or another closely related flavivirus or flavivirus vaccination. Further differentiation would require neutralisation testing

Conclusions Rapid and accurate diagnosis of ZIKV infection is an international priority. NAT has limited utility in ZIKV diagnosis because most patients are either asymptomatic or present for testing after the brief period of likely viral shedding. The greatest need and most difficult challenge is the development of commercially available antibody tests for the specific and sensitive diagnosis of recent ZIKV infection.

Conclusions Identifying ZIKV epitopes that do not cross-react with other flavivirus antigens could lead to virus specific tests As ZIKV becomes endemic in new areas it adds another layer to the diagnostic dilemma of flavivirus diagnosis

Cases Visited relatives in Caribbean for Xmas Returned to Aust febrile illness upon return requested Zika serology Zika IgG IFA: Pos (titre 640) Zika IgM IFA: Neg Den specific total antibody: Pos (titre 2560) Den IgM: Negative Neut testing: Zika: 80 Den 1and 3 Neg Den 2: 320 Den 4: 320 PCR negative

Acute and Convalescent testing Acute Zika IgG IFA: Pos (titre 640) Zika IgM IFA: Neg Den specific total antibody: Pos (titre 2560) Den IgM: Negative Neut testing: Zika: 80 Den 1: <10 Den 2: 320 Den 3: <10 Den 4: 320 PCR negative Convalescent Zika IgG IFA: Pos (titre 5120) Zika IgM IFA: Equvocal Den specific total antibody: Pos 5120 Den IgM: Negative Neut testing: Zika: 10,240 Den 1: <10 Den 2: 320 Den 3: <10 Den 4: 320 PCR negative Interpretation: Recent Zika virus infection, secondary flavivirus

Cases Visited Caribbean Returned to Aust febrile illness upon return requested Zika serology Zika IgG IFA: <10 Zika IgM IFA: <10 Den specific total antibody: Negative Den IgM: Negative PCR negative

Acute and Convalescent testing Acute Zika IgG IFA: <10 Zika IgM IFA: Neg Den specific total antibody: Neg Den IgM: Negative Neut testing: Zika: <10 PCR negative Convalescent Zika IgG IFA: Pos (titre 320) Zika IgM IFA: Pos Den specific total antibody: Neg Den IgM: Negative Neut testing: Zika: 1,280 PCR negative Interpretation: Recent Zika virus infection